These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 33418131)
1. Magnetic resonance imaging evaluation of nigrosome 1 and neuromelanin can assist Parkinson's disease diagnosis, but requires an expert neuroradiologist. De Pietro Franco Zorzenon C; Almeida Antônio Bienes GH; Duarte Alves E; Tobaru Tibana LA; Carrete Júnior H; Ballalai Ferraz H Parkinsonism Relat Disord; 2021 Feb; 83():8-12. PubMed ID: 33418131 [TBL] [Abstract][Full Text] [Related]
2. Multimodal assessment of nigrosomal degeneration in Parkinson's disease. Langley J; Huddleston DE; Crosson B; Song DD; Factor SA; Hu X Parkinsonism Relat Disord; 2020 Nov; 80():102-107. PubMed ID: 32979784 [TBL] [Abstract][Full Text] [Related]
3. Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson's disease. Taniguchi D; Hatano T; Kamagata K; Okuzumi A; Oji Y; Mori A; Hori M; Aoki S; Hattori N Mov Disord; 2018 Sep; 33(9):1488-1492. PubMed ID: 29756366 [TBL] [Abstract][Full Text] [Related]
4. Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: Combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson's disease. He N; Ghassaban K; Huang P; Jokar M; Wang Y; Cheng Z; Jin Z; Li Y; Sethi SK; He Y; Chen Y; Gharabaghi S; Chen S; Yan F; Haacke EM Neuroimage; 2021 Apr; 230():117810. PubMed ID: 33524572 [TBL] [Abstract][Full Text] [Related]
5. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients. Reimão S; Pita Lobo P; Neutel D; Correia Guedes L; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ Eur J Neurol; 2015 Mar; 22(3):540-6. PubMed ID: 25534480 [TBL] [Abstract][Full Text] [Related]
6. Nigrosome Imaging and Neuromelanin Sensitive MRI in Diagnostic Evaluation of Parkinsonism. Pavese N; Tai YF Mov Disord Clin Pract; 2018; 5(2):131-140. PubMed ID: 30363419 [TBL] [Abstract][Full Text] [Related]
7. A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy. Simões RM; Castro Caldas A; Grilo J; Correia D; Guerreiro C; Pita Lobo P; Valadas A; Fabbri M; Correia Guedes L; Coelho M; Rosa MM; Ferreira JJ; Reimão S BMC Neurol; 2020 Nov; 20(1):432. PubMed ID: 33243166 [TBL] [Abstract][Full Text] [Related]
8. Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease. Prasad S; Stezin A; Lenka A; George L; Saini J; Yadav R; Pal PK Eur J Neurol; 2018 Apr; 25(4):680-686. PubMed ID: 29341412 [TBL] [Abstract][Full Text] [Related]
9. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease. Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056 [TBL] [Abstract][Full Text] [Related]
10. Nigrosome and Neuromelanin Imaging as Tools to Differentiate Parkinson's Disease and Parkinsonism. Biswas D; Banerjee R; Sarkar S; Choudhury S; Sanyal P; Tiwari M; Kumar H Ann Indian Acad Neurol; 2022; 25(6):1029-1035. PubMed ID: 36911494 [TBL] [Abstract][Full Text] [Related]
15. Imaging the Nigrosome 1 in the substantia nigra using susceptibility weighted imaging and quantitative susceptibility mapping: An application to Parkinson's disease. Cheng Z; He N; Huang P; Li Y; Tang R; Sethi SK; Ghassaban K; Yerramsetty KK; Palutla VK; Chen S; Yan F; Haacke EM Neuroimage Clin; 2020; 25():102103. PubMed ID: 31869769 [TBL] [Abstract][Full Text] [Related]
16. Comparative Study of MRI Biomarkers in the Substantia Nigra to Discriminate Idiopathic Parkinson Disease. Pyatigorskaya N; Magnin B; Mongin M; Yahia-Cherif L; Valabregue R; Arnaldi D; Ewenczyk C; Poupon C; Vidailhet M; Lehéricy S AJNR Am J Neuroradiol; 2018 Aug; 39(8):1460-1467. PubMed ID: 29954816 [TBL] [Abstract][Full Text] [Related]
17. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes. Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900 [TBL] [Abstract][Full Text] [Related]
18. Predictive markers for Parkinson's disease using deep neural nets on neuromelanin sensitive MRI. Shinde S; Prasad S; Saboo Y; Kaushick R; Saini J; Pal PK; Ingalhalikar M Neuroimage Clin; 2019; 22():101748. PubMed ID: 30870733 [TBL] [Abstract][Full Text] [Related]
19. Automatic detection of neuromelanin and iron in the midbrain nuclei using a magnetic resonance imaging-based brain template. Jin Z; Wang Y; Jokar M; Li Y; Cheng Z; Liu Y; Tang R; Shi X; Zhang Y; Min J; Liu F; He N; Yan F; Haacke EM Hum Brain Mapp; 2022 Apr; 43(6):2011-2025. PubMed ID: 35072301 [TBL] [Abstract][Full Text] [Related]
20. The diagnostic value of SNpc using NM-MRI in Parkinson's disease: meta-analysis. Wang X; Zhang Y; Zhu C; Li G; Kang J; Chen F; Yang L Neurol Sci; 2019 Dec; 40(12):2479-2489. PubMed ID: 31392640 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]